Movement Disorders

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.

Research led by movement disorders specialist Un Jung Kang, MD, searches for clues to help diagnose and treat Parkinson’s disease in its earliest stages, well before symptom onset.

Here's what is coming soon to NeurologyLive.

The chief medical officer of Cerevel Therapeutics detailed the TEMPO trials, a trio of studies that will examine tavapadon in patients with early and late-stage Parkinson disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

Andrea Quattrone, MD, discusses how his team worked to create a simpler biomarker after developing MRPI 2.0.

The chief medical officer of CND Life Sciences and medical director of Honor Health Neurology spoke to the role synuclein has played in advancing PD diagnosis.

The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.

Raymond Sanchez, MD, chief medical officer of Cerevel Therapeutics, discussed tavapadon, a drug intended to treat Parkinson disease that is currently being tested in a slew of clinical trials.

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

Objective reduction in tremor was accompanied by improvement in specific motor tasks and a larger proportion of patients in the botulinum neurotoxin group reporting a global subjective improvement in symptoms.

Researchers from Northwestern University found nilotinib had an acceptable safety profile, but lacked efficacy that would encourage further study in patients with Parkinson disease.

Here's what is coming soon to NeurologyLive.

Catch up on the best and most listened to episodes of the NeurologyLive Mind Moments podcast, featuring exclusive interviews with experts in neurology.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD, and a number of others.

Look back on some of our most popular video interviews with experts in the field, including discussions on stroke, migraine, Parkinson disease, dementia, and more.

The approvals introduced several new agents into a number of patient populations, including much-needed additions to some diseases lacking a large number of options.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Here's what is coming soon to NeurologyLive.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss the neurologic symptoms associated with COVID-19.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how the pandemic affected mental health, specifically at an in-hospital setting.

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss the resources and tools used to adapt to the COVID-19 pandemic.

The Merz Therapeutics product, marketed as Xeomin, is the first and only FDA-approved neuromodulator available for patients aged 2 years and older with chronic sialorrhea.